DXCM DEXCOM INC

Nasdaq dexcom.com


$ 58.30 $ -9.98 (-14.63 %)    

Friday, 31-Oct-2025 17:53:58 EDT
QQQ $ 629.17 $ 3.02 (0.48 %)
DIA $ 475.66 $ 0.66 (0.14 %)
SPY $ 682.17 $ 2.23 (0.33 %)
TLT $ 90.34 $ -0.27 (-0.3 %)
GLD $ 368.39 $ -2.01 (-0.54 %)
$ 58.22
$ 59.56
$ 58.25 x 25
$ 58.50 x 55
$ 56.45 - $ 60.36
$ 56.45 - $ 93.25
26,543,718
na
22.71B
$ 1.29
$ 31.51
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-30-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 10-24-2024 09-30-2024 10-Q
6 07-25-2024 06-30-2024 10-Q
7 04-25-2024 03-31-2024 10-Q
8 02-08-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-09-2023 12-31-2022 10-K
13 10-27-2022 09-30-2022 10-Q
14 07-28-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 02-14-2022 12-31-2021 10-K
17 10-28-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 02-11-2021 12-31-2020 10-K
21 10-27-2020 09-30-2020 10-Q
22 07-28-2020 06-30-2020 10-Q
23 04-28-2020 03-31-2020 10-Q
24 02-13-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 07-31-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-21-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-01-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-01-2017 06-30-2017 10-Q
35 05-02-2017 03-31-2017 10-Q
36 02-28-2017 12-31-2016 10-K
37 11-01-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 04-27-2016 03-31-2016 10-Q
40 02-23-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-dexcom-lowers-price-target-to-93

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers the price target from $98 to...

 canaccord-genuity-maintains-buy-on-dexcom-lowers-price-target-to-99

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $106 t...

 citigroup-maintains-buy-on-dexcom-lowers-price-target-to-75

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $85 to $75.

 jp-morgan-maintains-neutral-on-dexcom-lowers-price-target-to-75

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and lowers the price target from $90 to $75.

 td-cowen-maintains-buy-on-dexcom-lowers-price-target-to-84

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $100 to $84.

 nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

 piper-sandler-maintains-overweight-on-dexcom-lowers-price-target-to-75

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers the price target from $10...

 rbc-capital-maintains-outperform-on-dexcom-lowers-price-target-to-85

RBC Capital analyst Shagun Singh maintains DexCom (NASDAQ:DXCM) with a Outperform and lowers the price target from $100 to $85.

 20-earnings-growth-potential-for-dexcom-analyst-cites-buying-opportunity

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margi...

 btig-maintains-buy-on-dexcom-lowers-price-target-to-85

BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $109 to $85.

 dexcom-raises-fy2025-sales-guidance-from-4600b-4625b-to-4630b-4650b-vs-4626b-est

DexCom (NASDAQ:DXCM) raises FY2025 sales outlook from $4.600 billion-$4.625 billion to $4.630 billion-$4.650 billion vs $4.626 ...

 dexcom-q3-adj-eps-061-beats-057-estimate-sales-1209b-beat-1179b-estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.57 by 7.39 ...

 meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

 an-overview-of-dexcoms-earnings
An Overview of DexCom's Earnings
10/29/2025 17:02:47

 dexcom-faces-new-reports-of-deaths-linked-to-g7-glucose-monitor

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION